MARKET

NRBO

NRBO

NeuroBo Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.76
-0.32
-3.96%
Opening 14:29 07/09 EDT
OPEN
8.01
PREV CLOSE
8.08
HIGH
8.12
LOW
7.62
VOLUME
51.92K
TURNOVER
--
52 WEEK HIGH
30.00
52 WEEK LOW
5.95
MARKET CAP
127.48M
P/E (TTM)
-0.5720
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NRBO stock price target is 25.00 with a high estimate of 30.00 and a low estimate of 20.00.

EPS

NRBO News

More
NeuroBo Pharmaceuticals to Join Russell 3000® and Microcap® Indexes
PR Newswire · 06/16 21:05
NeuroBo Pharmaceuticals to Join Russell 3000 and Microcap Indexes
Benzinga · 06/16 20:10
HC Wainwright & Co. Initiates Coverage On NeuroBo Pharmaceuticals with Buy Rating, Announces Price Target of $20
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announces Price Target of $20.
Benzinga · 06/15 11:48
NeuroBo Pharmaceuticals Announces Continuation Of Partial Clinical Hold Of Gemcabene
Benzinga · 05/26 12:40
NeuroBo Pharmaceuticals Announces Continuation of Partial Clinical Hold of Gemcabene
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it received written
PR Newswire · 05/26 12:30
NeuroBo Pharmaceuticals Reports First Quarter 2020 Financial Results
PR Newswire · 05/20 21:29
NeuroBo Pharmaceuticals Q1 EPS $(0.300) Up From $(0.480) YoY
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(0.300) per share. This is a 37.5 percent increase over losses of $(0.480) per share from the same period last year.
Benzinga · 05/20 20:30
NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders
PR Newswire · 04/21 13:30

Industry

Biotechnology & Medical Research
-0.28%
Pharmaceuticals & Medical Research
-0.70%

Hot Stocks

Symbol
Price
%Change

About NRBO

NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug.
More

Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRBO stock methods without spending real money on the virtual paper trading platform.